Gain Therapeutics (GANX)
Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas in Switzerland,...
- Open
- 1.830
- High
- 1.900
- Low
- 1.795
- Prev. Close
- 1.810
- Volume
- 272.64K
- Turnover
- 503.75K
- Avg Price
- 1.848
- Bid/Ask Ratio
- -61.11%
- Amplitude
- 5.80%
- 52wk High
- 4.340
- Volume Ratio
- 0.88
- Turnover Ratio
- 0.64%
Gain Therapeutics Analyst Rating
View moreForecast & Rating
Aug 18, 2026Price forecast
$7.20287.10%
Forecast & RatingStrong buy
5analysts
- Strong buy80.00%
- Buy20.00%
- Hold0.00%
- Sell0.00%
- Strong sell0.00%
News
- PUBT · 2 days ago, 06:02 AM
Gain Therapeutics joins H.C. Wainwright Global Investment Conference for investor meetings
- Earnings Watch · Aug 11 at 03:11 PM
Gain Therapeutics | 8-K: FY2026 Q2 Revenue: USD 0
- PUBT · Aug 11 at 06:04 AM
Gain Therapeutics Q2 FY26 net loss narrows to $0.11 a share; R&D expenses fall 24.64% to $2.1 million
- Global Report · Aug 5 at 04:13 AM
The American Economy in 2026 Is Splintering: What Ten Outliers Reveal
- Global Report · Jul 29 at 04:19 AM
The Unbundled Tail of the Market: From Volatility ETFs to Binary Biotech
- Global Report · Jul 21 at 04:13 AM
Market Insider: EV Charging Realities, Pharma Breakouts, and Under-the-Radar Movers
